Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 36% Improvement Relative Risk c19hcq.org Gómez et al. HCQ for COVID-19 LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 1,799 patients in Spain (March - October 2020) Lower mortality with HCQ (p<0.000001) Gómez et al., Medicina Clínica, doi:10.1016/j.medcle.2022.01.020 Favors HCQ Favors control
Mortality risk factors in patients with SARS-CoV-2 infection and atrial fibrillation: Data from the SEMI-COVID-19 registry
Gómez et al., Medicina Clínica (English Edition), doi:10.1016/j.medcle.2022.01.020
Gómez et al., Mortality risk factors in patients with SARS-CoV-2 infection and atrial fibrillation: Data from the.., Medicina Clínica (English Edition), doi:10.1016/j.medcle.2022.01.020
Oct 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 1,799 hospitalized COVID-19 patients with atrial fibrillation in Spain, showing lower mortality with HCQ treatment in unadjusted results. This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
risk of death, 35.8% lower, RR 0.64, p < 0.001, treatment 500 of 1,378 (36.3%), control 238 of 421 (56.5%), NNT 4.9.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Gómez et al., 13 Oct 2022, retrospective, Spain, peer-reviewed, 10 authors, study period 1 March, 2020 - 1 October, 2020.
Contact: manuel.mendez@salud.madrid.org.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Journal Pre-proof Mortality risk factors in patients with SARS-CoV-2 infection and atrial fibrillation: Data from the SEMI-COVID-19 registry Javier Azaña Gómez, Luis M. Pérez-Belmonte, Manuel Rubio-Rivas, Jose Bascuñana, Raul Quirós-López, Maria Luisa Taboada Martı́nez, Esther Montero Hernandez, Fernando Roque-Rojas, Manuel Méndez-Bailón, Ricardo Gómez-Huelgas, en nombre del grupo SEMI-COVID-19 PII: S2387-0206(22)00502-2 DOI: https://doi.org/10.1016/j.medcle.2022.01.020 Reference: MEDCLE 5908 To appear in: Medicina Clı́nica (English Edition) Received Date: 23 October 2021 Accepted Date: 10 January 2022 Please cite this article as: { doi: https://doi.org/ This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2020 Published by Elsevier. MEDCLI 5908 Original Mortality risk factors in patients with SARS-CoV-2 infection and atrial fibrillation: Data from the SEMI-COVID-19 registry ro of Factores de riesgo de mortalidad en pacientes con infección por SARS-CoV-2 y afectos de fibrilación auricular: datos del registro SEMI-COVID-19 Javier Azaña Gómez MD, 1, Luis M. Pérez-Belmonte, MD, PhD2, Manuel Rubio-Rivas MD3, Jose Bascuñana MD 4, Raul Quirós-López MD 5 , Maria Luisa Taboada Martínez MD 6, Esther Montero Hernandez 7, Fernando Roque-Rojas 8, Manuel Méndez-Bailón*, MD, PhD1 ¶ Ricardo Gómez-Huelgas, MD, PhD2 en nombre del grupo SEMI-COVID-19**. -p 1 Servicio de Medicina Interna, Hospital Clínico San Carlos, Universidad Complutense de Madrid, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, España. re 2 Servicio de Medicina Interna, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga (UMA)( Málaga), España. lP 3 Servicio de Medicina Interna. Hospital Universitario de Bellvitge-IDIBELL. L'Hospitalet de Llobregat (Barcelona), España 4 Servicio de Medicina Interna. Hospital Universitario 12 de Octubre. Madrid, España na 5. Servicio de Medicina Interna. Hospital Universitario Costa del Sol. Marbella (Málaga), España 6 Servicio de Medicina Interna. Hospital Universitario de Cabueñes. Gijón (Asturias),España ur 7 Servicio de Medicina Interna. Hospital Universitario Puerta de Hierro. Majadahonda (Madrid), España 8 Servicio de Medicina Interna. Hospital Universitario Infanta Cristina. Parla (Madrid), España Jo *Autor para correspondencia: Manuel Méndez Bailón. Dirección: Servicio de Medicina Interna, Hospital Universitario Clínico San Carlos. Calle del Profesor Martín Lagos, s/n, 28040, Madrid, España. Teléfono: 91 3303000. E-mail: manuel.mendez@salud.madrid.org ¶ Los doctores Méndez-Bailón y Gómez-Huelgas comparten la autoría final. 1 ** La lista completa de miembros del grupo SEMI-COVID-19 aparecen relacionados en el anexo. RESUMEN Introducción: La fibrilación auricular y las comorbilidades asociadas a ella suponen un factor de riesgo de mortalidad, morbilidad y desarrollo de complicaciones en..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit